(1-benzoyl-4-phenylpiperidine-4-yl)acetaldehyde | 716358-36-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1-benzoyl-4-phenylpiperidine-4-yl)acetaldehyde
• 英文别名: (1-Benzoyl-4-phenylpiperidin-4-yl)acetaldehyde；2-(1-benzoyl-4-phenylpiperidin-4-yl)acetaldehyde
• CAS: 716358-36-0
• 化学式: C₂₀H₂₁NO₂
• 分子量: 307.392
• InChiKey: MXEIHRGVDBFARS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1-benzoyl-4-phenylpiperidine-4-yl)acetaldehyde 、 endo-1-(8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole 在 三乙酰氧基硼氢化钠 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 endo-2-methyl-1-((1R,5S)-8-{2-[4-phenyl-1-(phenylcarbonyl)-4-piperidinyl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole
  参考文献：
  名称：

  Discovery of Bioavailable 4,4-Disubstituted Piperidines as Potent Ligands of the Chemokine Receptor 5 and Inhibitors of the Human Immunodeficiency Virus-1

  摘要：

  We describe robust chemical approaches toward putative CCR5 scaffolds designed in our laboratories. Evaluation of analogues in the (125)I-[MIP-1 beta] binding and Ba-L-HOS antiviral assays resulted in the discovery of 64 and 68 in the 4,4-disubstitited piperidine class H, both potent CCR5 ligands (pIC(50) = 8.30 and 9.00, respectively) and HIV-1 inhibitors (pIC(50) = 7.80 and 7.84, respectively, in Ba-L-HOS assay). In addition, 64 and 68 were bioavailable in rodents, establishing them as lead molecules for further optimization toward CCR5 clinical candidates.

  DOI：

  10.1021/jm800598a
• 作为产物：
  描述：

  tert-butyl 4-[(E/Z)-2-methoxyethenyl]-4phenylpiperidine-1-carboxylate 、 苯甲酰氯 在 盐酸 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 2.0h， 以41%的产率得到(1-benzoyl-4-phenylpiperidine-4-yl)acetaldehyde
  参考文献：
  名称：

  [EN] PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS
  [FR] ANTAGONISTES DE CCR5 UTILES COMME AGENTS THERAPEUTIQUES

  摘要：

  公开号：

  WO2004054974A3

文献信息

• Ccr5 antagonists as therapeutic agents
  申请人：Kazmierski Mieczyslaw Wieslaw

  公开号：US20060229336A1

  公开（公告）日：2006-10-12

  The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

  本发明涉及式(I)化合物或其药学上可接受的衍生物，用于预防CCR5相关疾病和障碍的治疗，例如，抑制HIV复制，预防或治疗HIV感染，以及治疗由此产生的获得性免疫缺陷综合症（AIDS）。
• CCR5 antagonists as therapeutic agents
  申请人：SmithKline Beecham Corp.

  公开号：US07645771B2

  公开（公告）日：2010-01-12

  The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

  本发明涉及式(I)化合物或其药学上可接受的衍生物，用于预防CCR5相关疾病和障碍的治疗，例如，在抑制HIV复制，预防或治疗HIV感染以及治疗由此引起的获得性免疫缺陷综合症（AIDS）方面。
• PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1569646A2

  公开（公告）日：2005-09-07
• US7645771B2
  申请人：——

  公开号：US7645771B2

  公开（公告）日：2010-01-12
• [EN] CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS<br/>[FR] ANTAGONISTES DE CCR5 UTILES COMME AGENTS THERAPEUTIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2004054974A2

  公开（公告）日：2004-07-01

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable derivatives thereof, useful in the treatment or prophylaxis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).